Hudson Portfolio Management LLC Takes $637,000 Position in Cigna Group $CI

Hudson Portfolio Management LLC acquired a new stake in shares of Cigna Group (NYSE:CI) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,312 shares of the health services provider’s stock, valued at approximately $637,000.

Other hedge funds have also bought and sold shares of the company. Assetmark Inc. lifted its stake in shares of Cigna Group by 10.0% during the 1st quarter. Assetmark Inc. now owns 65,662 shares of the health services provider’s stock valued at $17,515,000 after buying an additional 5,963 shares in the last quarter. Mystic Asset Management Inc. purchased a new stake in Cigna Group in the 2nd quarter worth $2,808,000. HighTower Advisors LLC increased its stake in Cigna Group by 402.7% in the 2nd quarter. HighTower Advisors LLC now owns 354,398 shares of the health services provider’s stock worth $97,701,000 after buying an additional 283,897 shares in the last quarter. KBC Group NV raised its holdings in Cigna Group by 6.4% during the second quarter. KBC Group NV now owns 380,034 shares of the health services provider’s stock valued at $104,768,000 after acquiring an additional 22,978 shares during the period. Finally, TD Asset Management Inc lifted its position in shares of Cigna Group by 4.8% in the second quarter. TD Asset Management Inc now owns 249,966 shares of the health services provider’s stock valued at $68,911,000 after acquiring an additional 11,471 shares in the last quarter. Hedge funds and other institutional investors own 86.99% of the company’s stock.

Cigna Group Stock Performance

Shares of NYSE:CI opened at $276.19 on Friday. The company has a market capitalization of $72.98 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 0.95 and a beta of 0.29. The firm’s 50-day moving average is $284.20 and its 200 day moving average is $281.38. Cigna Group has a 12 month low of $239.51 and a 12 month high of $315.47. The company has a current ratio of 0.76, a quick ratio of 0.76 and a debt-to-equity ratio of 0.68.

Cigna Group (NYSE:CI) last posted its quarterly earnings results on Thursday, July 30th. The health services provider reported $7.78 EPS for the quarter, topping the consensus estimate of $7.60 by $0.18. The company had revenue of $70.04 billion for the quarter, compared to the consensus estimate of $70.14 billion. Cigna Group had a net margin of 2.27% and a return on equity of 19.75%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $7.20 EPS. Cigna Group has set its FY 2026 guidance at 30.450- EPS. Research analysts predict that Cigna Group will post 30.51 EPS for the current year.

Cigna Group Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be issued a dividend of $1.56 per share. This represents a $6.24 annualized dividend and a yield of 2.3%. The ex-dividend date is Tuesday, September 8th. Cigna Group’s dividend payout ratio is presently 25.82%.

Insider Buying and Selling

In related news, insider Nicole S. Jones sold 19,436 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $276.27, for a total transaction of $5,369,583.72. Following the transaction, the insider directly owned 27,256 shares in the company, valued at $7,530,015.12. The trade was a 41.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jamie G. Kates sold 899 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $298.61, for a total transaction of $268,450.39. Following the sale, the chief accounting officer directly owned 2,368 shares in the company, valued at approximately $707,108.48. This represents a 27.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 23,012 shares of company stock worth $6,386,550. Insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CI. The Goldman Sachs Group upped their price objective on Cigna Group from $335.00 to $340.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. Piper Sandler decreased their target price on Cigna Group from $370.00 to $346.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Robert W. Baird set a $362.00 price target on Cigna Group in a report on Friday, July 31st. Sanford C. Bernstein increased their price objective on shares of Cigna Group from $371.00 to $381.00 and gave the company an “outperform” rating in a report on Thursday, July 9th. Finally, Wall Street Zen cut shares of Cigna Group from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cigna Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $339.45.

Cigna Group Profile

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.